Keyphrases
Melanoma
82%
Melanoma Cells
33%
AKT3
28%
Malignant Melanoma
24%
Melanocytic Tumor
18%
Tumor Development
16%
Aldehyde Dehydrogenase 2 (ALDH2)
15%
Apoptosis
15%
Metastasis
15%
Melanoma Development
14%
Melanoma Treatment
14%
B-Raf
14%
Cancer Cells
14%
Tumor
12%
Mitogen-activated Protein Kinase
12%
Small Interfering RNA (siRNA)
11%
Signaling Cascades
11%
Therapeutic Target
10%
Tumor Suppressor Gene
10%
Metastatic Melanoma
10%
Circulating Tumor Cells
9%
Drug Resistance
9%
Pharmacological Agents
9%
Nanotechnology
9%
Nanoliposomal
9%
In Cancer
8%
Cell Proliferation
8%
Therapeutic Agents
8%
Leelamine
8%
Cell Population
8%
Human Melanoma
8%
AKT Pathway
8%
Melanocytic Lesions
7%
Lesion Development
7%
Anticancer Activity
7%
Deregulation
7%
Human Chromosomes
7%
EEF2
7%
EEF2 Kinase
7%
Tumor Suppressor
7%
Chromosome 11
7%
WEE1
6%
Celecoxib
6%
Tumor Cells
6%
Phosphoinositide 3-kinase (PI3K)
5%
Tumorigenicity
5%
Human Melanoma Cells
5%
Cancer Cell Survival
5%
Tumor Suppression
5%
Leukemia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Malignant Neoplasm
48%
Neoplasm
42%
Aldehyde Dehydrogenase
17%
Mitogen Activated Protein Kinase
14%
Small Interfering RNA
12%
Nanoparticle
11%
Tumor Growth
11%
Aldehyde Dehydrogenase Inhibitor
9%
Protein Kinase B
9%
Drug Resistance
9%
Lung Metastasis
7%
Diseases
7%
Metastatic Melanoma
6%
Celecoxib
6%
Protein Kinase B Inhibitor
6%
Protein P53
5%
Phosphotransferase
5%
Liposome
5%
Anticancer Drug
5%
Ceramide
5%
Casein Kinase
5%
Combination Therapy
5%
Medicine and Dentistry
Nodular Melanoma
45%
Melanoma Cell
33%
Neoplasm
28%
Malignant Neoplasm
18%
Metastatic Carcinoma
16%
Cancer Cell
14%
Programmed Cell Death
14%
Mitogen-Activated Protein Kinase
11%
Circulating Tumor Cell
10%
Metastatic Melanoma
8%
Protein Kinase B
7%
Small Interfering RNA
7%
Phosphotransferase
7%
Cell Proliferation
7%
Cholesterol Transport
6%
Cell Signaling Pathway
6%
Lung Metastasis
6%
Tumor Cell
6%
Diseases
5%
Drug Resistance
5%
Tumor Progression
5%
Granulocyte
5%
Cancer Therapy
5%
Neutrophil
5%
Immunotherapy
5%
Akt Signaling
5%